Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support

Background: Heart failure (HF) alters the nucleo-cytoplasmic transport of cardiomyocytes and reduces SERCA2a levels, essential for intracellular calcium homeostasis. We consider in this study whether the molecules involved in these processes can differentiate those patients with advanced HF and the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2021-10, Vol.11 (11), p.1122
Main Authors: Ezzitouny, Meryem, Roselló-Lletí, Esther, Portolés, Manuel, Sánchez-Lázaro, Ignacio, Arnau-Vives, Miguel Ángel, Tarazón, Estefanía, Gil-Cayuela, Carolina, Lozano-Edo, Silvia, López-Vilella, Raquel, Almenar-Bonet, Luis, Martínez-Dolz, Luis
Format: Article
Language:English
Subjects:
Adenosine triphosphatase
Biobanks
Biomarkers
Ca2+-transporting ATPase
Calcium (intracellular)
Calcium (reticular)
Calcium homeostasis
Cardiomyocytes
Congestive heart failure
Enzymes
Heart failure
Heart transplantation
Homeostasis
Normal distribution
Patients
Plasma levels
Precision medicine
Sarcoplasmic reticulum
Surgical apparatus & instruments
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Heart failure (HF) alters the nucleo-cytoplasmic transport of cardiomyocytes and reduces SERCA2a levels, essential for intracellular calcium homeostasis. We consider in this study whether the molecules involved in these processes can differentiate those patients with advanced HF and the need for mechanical circulatory support (MCS) as a bridge to recovery or urgent heart transplantation from those who are clinically stable and who are transplanted in an elective code. Material and method: Blood samples from 29 patients with advanced HF were analysed by ELISA, and the plasma levels of Importin5, Nucleoporin153 kDa, RanGTPase-Activating Protein 1 and sarcoplasmic reticulum Ca2+ ATPase were compared between patients requiring MCS and those patients without a MCS need prior to heart transplantation. Results: SERCA2a showed significantly lower levels in patients who had MCS compared to those who did not require it (0.501 ± 0.530 ng/mL vs. 1.123 ± 0.661 ng/mL; p = 0.01). A SERCA2a cut-off point of 0.84 ng/mL (AUC 0.812 ± 0.085, 95% CI: 0.646–0.979; p = 0.004) provided a 92% sensitivity, 62% specificity, 91% negative predictive value and 67% positive predictive value. Conclusions: In this cohort, patients with advanced HF and a need for MCS have shown significantly lower levels of SERCA2a as compared to stable patients without a need for MCS prior to heart transplantation. This is a small study with preliminary findings, and larger-powered dedicated studies are required to confirm and validate these results.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm11111122